Kura Oncology Investors Await Crucial FDA Verdict

The biotechnology sector is watching closely as Kura Oncology approaches a pivotal moment in its corporate history. With the FDA’s decision on its flagship drug candidate Ziftomenib scheduled for November 30, 2025, the company stands at a critical juncture. Recent financial disclosures reveal escalating operational costs, creating a high-stakes environment for shareholders.

Kura Oncology’s financial position showed increased pressure in the third quarter of 2025. The company reported a net loss of $74.1 million, significantly wider than the $54.4 million deficit recorded during the same period last year. Earnings per share came in at a loss of $0.85, falling short of analyst projections. This negative trend primarily stemmed from substantially increased research and development expenditures, which surged Read more...